|
1
|
Ng SC, Shi HY, Hamidi N, Underwood FE,
Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et
al: Worldwide incidence and prevalence of inflammatory bowel
disease in the 21st century: A systematic review of
population-based studies. Lancet. 390:2769–2778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beaugerie L and Itzkowitz SH: Cancers
complicating inflammatory bowel disease. N Engl J Med.
372:1441–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crohn BB and Rosenberg H: The
sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci.
170:220–228. 1925. View Article : Google Scholar
|
|
4
|
Rubin DT, Ananthakrishnan AN, Siegel CA,
Sauer BG and Long MD: ACG clinical guideline: Ulcerative colitis in
adults. Am J Gastroenterol. 114:384–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network, .
NCCN clinical practice guidelines in oncology-colon cancer (version
1. 2022). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf28–July.
2022
|
|
6
|
Robles AI, Traverso G, Zhang M, Roberts
NJ, Khan MA, Joseph C, Lauwers GY, Selaru FM, Popoli M, Pittman ME,
et al: Whole-exome sequencing analyses of inflammatory bowel
disease-associated colorectal cancers. Gastroenterology.
150:931–943. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grivennikov SI and Cominelli F:
Colitis-associated and sporadic colon cancers: Different diseases,
different mutations? Gastroenterology. 150:808–810. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yaeger R, Shah MA, Miller VA, Kelsen JR,
Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, et al:
Genomic alterations observed in colitis-associated cancers are
distinct from those found in sporadic colorectal cancers and vary
by type of inflammatory bowel disease. Gastroenterology.
151:278–287.e6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita M, Matsubara N, Matsuda I, Maejima
K, Oosawa A, Yamano T, Fujimoto A, Furuta M, Nakano K, Oku-Sasaki
A, et al: Genomic landscape of colitis-associated cancer indicates
the impact of chronic inflammation and its stratification by
mutations in the Wnt signaling. Oncotarget. 9:969–981. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka T, Kobunai T, Yamamoto Y, Emoto S,
Murono K, Kaneko M, Sasaki K, Otani K, Nishikawa T, Kawai K, et al:
Colitic cancer develops through mutational alteration distinct from
that in sporadic colorectal cancer: A comparative analysis of
mutational rates at each step. Cancer Genomics Proteomics.
14:341–348. 2017.PubMed/NCBI
|
|
11
|
Din S, Wong K, Mueller MF, Oniscu A,
Hewinson J, Black CJ, Miller ML, Jiménez-Sánchez A, Rabbie R,
Rashid M, et al: Mutational analysis identifies therapeutic
biomarkers in inflammatory bowel disease-associated colorectal
cancers. Clin Cancer Res. 24:5133–5142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan P, Wang Y, Meng X, Yang H, Liu Z, Qian
J, Zhou W and Li J: Whole exome sequencing of ulcerative
colitis-associated colorectal cancer based on novel somatic
mutations identified in Chinese patients. Inflamm Bowel Dis.
25:1293–1301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baker AM, Cross W, Curtius K, Al Bakir I,
Choi CR, Davis HL, Temko D, Biswas S, Martinez P, Williams MJ, et
al: Evolutionary history of human colitis-associated colorectal
cancer. Gut. 68:985–995. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alpert L, Yassan L, Poon R, Kadri S, Niu
N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, et al:
Targeted mutational analysis of inflammatory bowel
disease-associated colorectal cancers. Hum Pathol. 89:44–50. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wanders LK, Cordes M, Voorham Q, Sie D, de
Vries SD, d'Haens GRAM, de Boer NKH, Ylstra B, van Grieken NCT,
Meijer GA, et al: IBD-associated dysplastic lesions show more
chromosomal instability than sporadic adenomas. Inflamm Bowel Dis.
26:167–180. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirsch D, Hardt J, Sauer C,
Heselmeyer-Hadded K, Witt SH, Kienle P, Ried T and Gaiser T:
Molecular characterization of ulcerative colitis-associated
colorectal carcinomas. Mod Pathol. 34:1153–1166. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsumoto K, Urabe Y, Oka S, Inagaki K,
Tanaka H, Yuge R, Hayashi R, Kitadai Y, Arihiro K, Shimamoto F, et
al: Genomic landscape of early-stage colorectal neoplasia
developing from the ulcerative colitis mucosa in the Japanese
population. Inflamm Bowel Dis. 27:686–696. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mäki-Nevala S, Ukwattage S, Olkinuora A,
Almusa H, Ahtiainen M, Ristimäki A, Seppälä T, Lepistö A, Mecklin
JP and Peltomäki P: Somatic mutation profiles as molecular
classifiers of ulcerative colitis-associated colorectal cancer. Int
J Cancer. 148:2997–3007. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rajamäki K, Taira A, Katainen R, Välimäki
N, Kuosmanen A, Plaketti RM, Seppälä TT, Ahtiainen M, Wirta EV,
Vartiainen E, et al: Genetic and epigenetic characteristics of
inflammatory bowel disease-associated colorectal cancer.
Gastroenterology. 161:592–607. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kameyama H, Nagahashi M, Shimada Y, Tajima
Y, Ichikawa H, Nakano M, Sakata J, Kobayashi T, Narayanan S, Takabe
K and Wakai T: Genomic characterization of colitis-associated
colorectal cancer. World J Surg Oncol. 16:1212018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagahashi M, Shimada Y, Ichikawa H,
Kameyama H, Takabe K, Okuda S and Wakai T: Next generation
sequencing-based gene panel tests for the management of solid
tumors. Cancer Sci. 110:6–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagahashi M, Wakai T, Shimada Y, Ichikawa
H, Kameyama H, Kobayashi T, Sakata J, Yagi R, Sato N, Kitagawa Y,
et al: Genomic landscape of colorectal cancer in Japan: Clinical
implications of comprehensive genomic sequencing for precision
medicine. Genome Med. 8:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimada Y, Yagi R, Kameyama H, Nagahashi
M, Ichikawa H, Tajima Y, Okamura T, Nakano M, Nakano M, Sato Y, et
al: Utility of comprehensive genomic sequencing for detecting
HER2-positive colorectal cancer. Hum Pathol. 66:1–9. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oyanagi H, Shimada Y, Nagahashi M,
Ichikawa H, Tajima Y, Abe K, Nakano M, Kameyama H, Takii Y,
Kawasaki T, et al: SMAD4 alteration associates with invasive-front
pathological markers and poor prognosis in colorectal cancer.
Histopathology. 74:873–882. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimada Y, Muneoka Y, Nagahashi M,
Ichikawa H, Tajima Y, Hirose Y, Ando T, Nakano M, Sakata J,
Kameyama H, et al: BRAF V600E and SRC mutations as molecular
markers for predicting prognosis and conversion surgery in Stage IV
colorectal cancer. Sci Rep. 9:24662019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsumoto A, Shimada Y, Nakano M, Oyanagi
H, Tajima Y, Nakano M, Kameyama H, Hirose Y, Ichikawa H, Nagahashi
M, et al: RNF43 mutation is associated with aggressive tumor
biology along with BRAF V600E mutation in right-sided colorectal
cancer. Oncol Rep. 43:1853–1862. 2020.PubMed/NCBI
|
|
27
|
Shimada Y, Okuda S, Watanabe Y, Tajima Y,
Nagahashi M, Ichikawa H, Nakano M, Sakata J, Takii Y, Kawasaki T,
et al: Histopathological characteristics and artificial
intelligence for predicting tumor mutational burden-high colorectal
cancer. J Gastroenterol. 56:547–559. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer International; New York, NY: 2017, View Article : Google Scholar
|
|
29
|
Laine L, Kaltenbach T, Barkun A, McQuaid
KR, Subramanian V and Soetikno R; SCENIC guideline development
panel, : SCENIC international consensus statement on surveillance
and management of dysplasia in inflammatory bowel disease.
Gastroenterology. 148:639–651.e28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konishi F, Wakasa H, Kino I, Watanabe H,
Nagura H and Muto T: Histological classification of the neoplastic
changes arising in ulcerative colitis: A new proposal in Japan. J
Gastroenterol. 30 (Suppl 8):20–24. 1995.PubMed/NCBI
|
|
31
|
Riddell RH, Goldman H, Ransohoff DF,
Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton
SR and Morson BC: Dysplasia in inflammatory bowel disease:
Standardized classification with provisional clinical applications.
Hum Pathol. 14:931–968. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Matsuda K, Watanabe H, Ajioka Y, Kobayashi
M, Saito H, Sasaki M, Yasuda K, Kuwabara A, Nishikura K and Muto T:
Ulcerative colitis with overexpression of p53 preceding overt
histological abnormalities of the epithelium. J Gastroenterol.
31:860–867. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gehring JS, Fischer B, Lawrence M and
Huber W: SomaticSignatures: Inferring mutational signatures from
single-nucleotide variants. Bioinformatics. 31:3673–3675.
2015.PubMed/NCBI
|
|
34
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Serra S and Chetty R: Rnf43. J Clin
Pathol. 71:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brentnall TA, Crispin DA, Rabinovitch PS,
Haggitt RC, Rubin CE, Stevens AC and Burmer GC: Mutations in the
p53 gene: An early marker of neoplastic progression in ulcerative
colitis. Gastroenterology. 107:369–378. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schulmann K, Mori Y, Croog V, Yin J, Olaru
A, Sterian A, Sato F, Wang S, Xu Y, Deacu E, et al: Molecular
phenotype of inflammatory bowel disease-associated neoplasms with
microsatellite instability. Gastroenterology. 129:74–85. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a germline
BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arena S, Corti G, Durinikova E, Montone M,
Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, et
al: A subset of colorectal cancers with cross-sensitivity to
olaparib and oxaliplatin. Clin Cancer Res. 26:1372–1384. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moretto R, Elliott A, Zhang J, Arai H,
Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, et
al: Homologous recombination deficiency alterations in colorectal
cancer: Clinical, molecular, and prognostic implications. J Natl
Cancer Inst. 114:271–279. 2022. View Article : Google Scholar : PubMed/NCBI
|
